High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology
Kovari et al. assessed treatment uptake and outcome parameters among HIV/HCV-coinfected people since the availability of HCV therapy in the SHCS. Seventeen percent of all SHCS participants harbored a replicating HCV infection. Of those, 30% were treated and 15% were cured during a follow-up period of thirteen years. Sixteen percent of participants with active HCV-infection died, 59% due to extrahepatic complications. By the end of 2013, 41% of patients with a replicating HCV infection remained to be treated.
The findings underscore the importance of efforts for optimizing care of comorbidities in HIV/HCV-coinfected patients, given that curing HCV alone is not sufficient to achieve mortality rates similar to HIV-monoinfected patient.